Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,592,351
  • Shares Outstanding, K 28,748
  • Annual Sales, $ 234,600 K
  • Annual Income, $ -13,230 K
  • EBIT $ 48 M
  • EBITDA $ 46 M
  • 60-Month Beta 0.32
  • Price/Sales 7.03
  • Price/Cash Flow N/A
  • Price/Book 42.71

Options Overview Details

View History
  • Implied Volatility 82.43% (+0.29%)
  • Historical Volatility 69.91%
  • IV Percentile 51%
  • IV Rank 22.49%
  • IV High 161.61% on 09/24/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 17) 6.89 (12.40%)
  • Put/Call Vol Ratio 0.58
  • Today's Volume 19
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 603
  • Open Int (30-Day) 680
  • Expected Range 48.63 to 62.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.72
  • Number of Estimates 7
  • High Estimate $0.46
  • Low Estimate $-1.56
  • Prior Year $-1.28
  • Growth Rate Est. (year over year) +43.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.68 +5.37%
on 03/03/26
68.39 -18.83%
on 03/17/26
+0.46 (+0.84%)
since 02/27/26
3-Month
42.00 +32.17%
on 01/06/26
68.39 -18.83%
on 03/17/26
+5.41 (+10.80%)
since 12/26/25
52-Week
15.40 +260.45%
on 04/09/25
68.39 -18.83%
on 03/17/26
+36.56 (+192.93%)
since 03/28/25

Most Recent Stories

More News
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one...

ANAB : 55.51 (+0.22%)
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026...

ANAB : 55.51 (+0.22%)
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and...

ANAB : 55.51 (+0.22%)
Upwing Energy Achieves ISO 9001:2015 Certification for Production of its Subsurface Compressor System

Upwing Energy, a leader in advanced compression technology for the oil and gas industry, has achieved ISO 9001:2015 certification for the production of its Subsurface Compressor Systems for improved natural...

ANAB : 55.51 (+0.22%)
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease...

ANAB : 55.51 (+0.22%)
Anaptys Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 55.51 (+0.22%)
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage...

ANAB : 55.51 (+0.22%)
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 55.51 (+0.22%)
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall...

ANAB : 55.51 (+0.22%)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

ANAB : 55.51 (+0.22%)
VNDA : 6.91 (+3.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 62.51
2nd Resistance Point 60.74
1st Resistance Point 58.07
Last Price 55.51
1st Support Level 53.62
2nd Support Level 51.85
3rd Support Level 49.18

See More

52-Week High 68.39
Last Price 55.51
Fibonacci 61.8% 48.15
Fibonacci 50% 41.90
Fibonacci 38.2% 35.64
52-Week Low 15.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.